Digene: powerful groups favor HPV test

Published By Datamonitor

Prostate cancer: new study could clear up vitamin E debate

Published By Datamonitor

Governmental cost-cutting helps generate generics growth

The generic cancer market was worth $1.3 billion in 2004 and is expected to reach $10.9 billion by 2014. This staggering level of growth is attributable to upcoming patent expiries on key products, as well as the imminent introduction of a biogenerics regulatory pathway. However, increasingly cost-conscious governments working to cut healthcare spending will remain generics firms' greatest ally.

Published By Datamonitor

Lung cancer: a targeted pipeline

Published By Datamonitor

Adult acute leukemia: demand for innovative drugs that prolong survival

A new report estimates that there will be approximately 84,000 cases of adult and childhood leukemia in the world's seven major pharmaceutical markets in 2006. Acute leukemias will account for 43% of these cases, and, although this market is relatively small compared to other cancer types, the clear unmet needs and regulatory incentives should help encourage drug makers.

Published By Datamonitor

Colorectal cancer: Amgen's pipeline drug set to overtake Erbitux

Published By Datamonitor

Cancer treatment: supportive care still needed

The treatment of cancer is shifting towards molecular targeted therapies, which are generally associated with fewer and milder side effects, indicating that the need for traditional supportive care measures may decrease in the future. However, these new products may be associated with their own unique set of side effects and supportive care measures will need to change to meet these requirements.

Published By Datamonitor

Therapeutic cancer vaccine market: antigen-specific therapies lead the way

Published By Datamonitor

Melanoma market: rising incidence represents significant opportunities

Published By Datamonitor

Cervical cancer: vaccines set to drastically reduce incidence

Despite a significant drop in the incidence of cervical cancer in the western world due to routine screening, cervical cancer remains the second most common cancer in women the world over. However, two new vaccines for the human papilloma virus (HPV), a major risk factor for cervical cancer, are set to have a dramatic impact on the incidence of cervical cancer all over the globe.

Published By Datamonitor